肛管癌治疗进展

doi:10.3877/cma.j.issn.2095-3224.2016.01.06

肛管癌的发病在过去几十年明显升高，并且未来也将呈持续升高态势。随着对于肛管癌生物学行为的认识深入，治疗模式发生了根本性的改变。主要的治疗手段已经不再是有创的手术切除，放射治疗同步化疗不仅可以达到根治目的，而且避免了腹会阴联合切除术给患者带来人工肛门的困扰。同步放化疗作为一线治疗，其应用越来越广泛。5氟尿嘧啶＋丝裂霉素在肛管癌的治疗中有明确的作用，可以提高完全缓解率、提高保肛率和无病生存率。当患者在同步放化疗结束后仍有肿瘤残存时，可以尝试挽救性同步放化疗或密切随诊，如果随诊肿瘤进展再行手术挽救。IMRT技术的应用，利于提高肛门区癌的剂量，同时保护小肠、膀胱、皮肤和股骨头等周围器官从而降低治疗副反应，减少治疗中断时间。靶向药物的应用给肛门癌的治疗带来了新的选择，但是有效性和安全性，需要更多研究数据支持。

关键词: 肛管, 治疗, 同步放化疗, 进展

The incidence of anal cancer has increased significantly in the past few decades, and it will present a rising trend in the future. As for deeper understanding of the biological behavior of anal cancer, the treatment modality has changed. Primary treatment is no longer invasive surgical resection, concurrent chemo-radiotherapy could not only achieve the curative purpose, but also avoid the abdominal perineal resection of patients with poor quality of life. Concurrent chemo-radiotherapy as first-line treatment of anal cancer, which has been proven by many studies, is applied more and more widely. 5-fluorouracil and mitomycin C as concurrent chemotherapy regimen could improve the complete remission rate, sphincter preservation rate and disease-free survival rate. Residual tumor after concurrent chemo-radiotherapy could be treated by salvage surgery. The application of IMRT technology could improve the dosimetry of radiotherapy, while protecting the small intestine, bladder, skin and the femoral head to reduce the side effects of treatment, to minimize the interruption of treatment. Molecular targeted drugs added to the treatment of anal cancer has brought new options, but the effectiveness and safety of the combination need more results from more prospective studies.

Key words: Anal canal, Treatment, Concurrent chemo-radiotherapy, Progress

表1 同步放化疗与单纯放疗比较的研究表

研究（年份）	入组条件	放疗	同步化疗	分组	病例数	结肠造瘘率	P值	局部区域复发率	P值	总生存率	p值
UKCCCR（1996）	肛管或肛周癌，可局部切除T1病变以外的任何分期	45 Gy/20~25 F完成6周后评价肿瘤缩小≥50%的患者建议加量15 Gy/6 F或I192插植	5FU（1000 mg/㎡/d, d1~4或者750 mg/㎡/d, d1~5）civ，分别于放疗第一周和最后一周给予；MMC iv（12 mg/㎡），d1	RT＋5FU＋MMC	292	24%	-	3 y 30%	<0.001	3 y 65%	0.12
UKCCCR（1996）	肛管或肛周癌，可局部切除T1病变以外的任何分期	45 Gy/20~25 F完成6周后评价肿瘤缩小≥50%的患者建议加量15 Gy/6 F或I192插植		RT	285	40%	-	3 y 53%	<0.001	3 y 60%	0.12
EORTC（1997）	肛管或肛周癌，T3-4N0-3或T1-2N1-3，PS 0~1，年龄<76岁	45 Gy/25 F完成6周后加量（完全缓解者15 Gy/6 F，未完全缓解者20 Gy）	5FU 750 mg/㎡/d, d1~5, d29~33, civ；MMC iv 15 mg/㎡，d1	RT＋5FU＋MMC	51	5 y 28%	0.002	5 y 32%	0.02	5 y 58%	0.17
EORTC（1997）	肛管或肛周癌，T3-4N0-3或T1-2N1-3，PS 0~1，年龄<76岁	45 Gy/25 F完成6周后加量（完全缓解者15 Gy/6 F，未完全缓解者20 Gy）	5FU 750 mg/㎡/d, d1~5, d29~33, civ；MMC iv 15 mg/㎡，d1	RT	52	5 y 60%	0.002	5 y 48%	0.02	5 y 53%	0.17

表1 同步放化疗与单纯放疗比较的研究表

研究（年份）	入组条件	放疗	同步化疗	分组	病例数	结肠造瘘率	P值	局部区域复发率	P值	总生存率	p值
UKCCCR（1996）	肛管或肛周癌，可局部切除T1病变以外的任何分期	45 Gy/20~25 F完成6周后评价肿瘤缩小≥50%的患者建议加量15 Gy/6 F或I192插植	5FU（1000 mg/㎡/d, d1~4或者750 mg/㎡/d, d1~5）civ，分别于放疗第一周和最后一周给予；MMC iv（12 mg/㎡），d1	RT＋5FU＋MMC	292	24%	-	3 y 30%	<0.001	3 y 65%	0.12
UKCCCR（1996）	肛管或肛周癌，可局部切除T1病变以外的任何分期	45 Gy/20~25 F完成6周后评价肿瘤缩小≥50%的患者建议加量15 Gy/6 F或I192插植		RT	285	40%	-	3 y 53%	<0.001	3 y 60%	0.12
EORTC（1997）	肛管或肛周癌，T3-4N0-3或T1-2N1-3，PS 0~1，年龄<76岁	45 Gy/25 F完成6周后加量（完全缓解者15 Gy/6 F，未完全缓解者20 Gy）	5FU 750 mg/㎡/d, d1~5, d29~33, civ；MMC iv 15 mg/㎡，d1	RT＋5FU＋MMC	51	5 y 28%	0.002	5 y 32%	0.02	5 y 58%	0.17
EORTC（1997）	肛管或肛周癌，T3-4N0-3或T1-2N1-3，PS 0~1，年龄<76岁	45 Gy/25 F完成6周后加量（完全缓解者15 Gy/6 F，未完全缓解者20 Gy）	5FU 750 mg/㎡/d, d1~5, d29~33, civ；MMC iv 15 mg/㎡，d1	RT	52	5 y 60%	0.002	5 y 48%	0.02	5 y 53%	0.17

表2 放疗同步不同化疗方案比较的研究表

研究（年份）	入组条件	放疗	分组	化疗方案	病例数	结肠造瘘率	P值	局部区域复发率	P值	总生存率	P值	无病生存率	P值
RTOF8704/ECOG1289(1996)	肛管癌，任何T或N分期，KPS≥60分	45 Gy/25 F完成4~6周后未完全缓解者加量9 Gy/5 F	RT+5FU/MMC	5FU 750 mg/m²/d, d1~5, d29~33, civ; MMC iv 10 mg/m², d1, d29	146	4 y 9%	0.002	4 y 16%	0.0008	4 y 76%	0.31	4 y 73%	0.0003
RTOF8704/ECOG1289(1996)	肛管癌，任何T或N分期，KPS≥60分	45 Gy/25 F完成4~6周后未完全缓解者加量9 Gy/5 F	RT+5FU	FU 750 mg/m²/d, d1~5, d29~33, civ	145	4 y 22%	0.002	4 y 34%	0.0008	4 y 67%	0.31	4 y 51%	0.0003
RTOG9811(1997, 2012)	肛管癌，T2-4任何NM0，KPS ≥60，年龄≥18岁	45 Gy/25 F	RT+5FU/MMC	5FU 1000 mg/m²/d, d1~4, d29~32, civ; MMC iv 10 mg/m², d1, d29	325	5 y 10%	0.02	5 y 25%	0.07	5 y 75%	0.10	5 y 60%	0.17
RTOG9811(1997, 2012)	肛管癌，T2-4任何NM0，KPS ≥60，年龄≥18岁	45 Gy/25 F, T3T4N+或者T2残存立即计量10~14 Gy/5~7 f完成6周后量	5FU/DDP x2RT+5FU/DDP	5FU 1000 mg/m²/d, d1~4, 29~32, 57~60, 85~88; DDP 75 mg/m², d1, 29, 57, 85	324	5 y 19%	0.02	5 y 33%	0.07	5 y 70%	0.10	5 y 54%	0.17
ACCORD03(2012)	肛管鳞癌，T2-4任何NM0或T1-2N1-3M0, PS 0~1,年龄18~80	45 Gy/25 F加量15~20 Gy	5FU/DDP x2 RT+5FU/DDP	5FU 800 mg/m²/d, civ, d1~4; DDP 80 mg/m², d1; W1, 5, 9, 12	150	-	-	-	-	5 y 74.5%	0.81	-	-
ACCORD03(2012)	肛管鳞癌，T2-4任何NM0或T1-2N1-3M0, PS 0~1,年龄18~80	45 Gy/25 F加量15~20 Gy	RT+5FU/DDP	5FU 800 mg/m²/d, civ, d1~4; DDP 80 mg/m², d1; W1, 5	157	-	-	-	-	5 y 71%	?	-	-
ACT II	肛管或肛周癌，任何T任何NM0	50.4 Gy/28 F	RT+5FU/MMC	5FU 1000 mg/m²/d, civ, d1~4, 29~32; MMC iv 12 mg/m², d1	246	23%	-	?	-	DDP:77% MMC:79%辅助：76%未辅助：79%	NS	?	NS
			RT+5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; DDP 60 mg/m², d1, 29	246	26%		?				?
			RT+5FU/MMC-5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; MMC iv 12 mg/m², d1辅助化疗5FU 1000 mg/m²/d, civ, d71~74, 92~95; DDP 60 mg/m², d71, 92	226	23%		?				?
			RT+5FU/DDP-5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; DDP 60 mg/m², d1, 29辅助化疗同上	222	22%		?				?

表2 放疗同步不同化疗方案比较的研究表

研究（年份）	入组条件	放疗	分组	化疗方案	病例数	结肠造瘘率	P值	局部区域复发率	P值	总生存率	P值	无病生存率	P值
RTOF8704/ECOG1289(1996)	肛管癌，任何T或N分期，KPS≥60分	45 Gy/25 F完成4~6周后未完全缓解者加量9 Gy/5 F	RT+5FU/MMC	5FU 750 mg/m²/d, d1~5, d29~33, civ; MMC iv 10 mg/m², d1, d29	146	4 y 9%	0.002	4 y 16%	0.0008	4 y 76%	0.31	4 y 73%	0.0003
RTOF8704/ECOG1289(1996)	肛管癌，任何T或N分期，KPS≥60分	45 Gy/25 F完成4~6周后未完全缓解者加量9 Gy/5 F	RT+5FU	FU 750 mg/m²/d, d1~5, d29~33, civ	145	4 y 22%	0.002	4 y 34%	0.0008	4 y 67%	0.31	4 y 51%	0.0003
RTOG9811(1997, 2012)	肛管癌，T2-4任何NM0，KPS ≥60，年龄≥18岁	45 Gy/25 F	RT+5FU/MMC	5FU 1000 mg/m²/d, d1~4, d29~32, civ; MMC iv 10 mg/m², d1, d29	325	5 y 10%	0.02	5 y 25%	0.07	5 y 75%	0.10	5 y 60%	0.17
RTOG9811(1997, 2012)	肛管癌，T2-4任何NM0，KPS ≥60，年龄≥18岁	45 Gy/25 F, T3T4N+或者T2残存立即计量10~14 Gy/5~7 f完成6周后量	5FU/DDP x2RT+5FU/DDP	5FU 1000 mg/m²/d, d1~4, 29~32, 57~60, 85~88; DDP 75 mg/m², d1, 29, 57, 85	324	5 y 19%	0.02	5 y 33%	0.07	5 y 70%	0.10	5 y 54%	0.17
ACCORD03(2012)	肛管鳞癌，T2-4任何NM0或T1-2N1-3M0, PS 0~1,年龄18~80	45 Gy/25 F加量15~20 Gy	5FU/DDP x2 RT+5FU/DDP	5FU 800 mg/m²/d, civ, d1~4; DDP 80 mg/m², d1; W1, 5, 9, 12	150	-	-	-	-	5 y 74.5%	0.81	-	-
ACCORD03(2012)	肛管鳞癌，T2-4任何NM0或T1-2N1-3M0, PS 0~1,年龄18~80	45 Gy/25 F加量15~20 Gy	RT+5FU/DDP	5FU 800 mg/m²/d, civ, d1~4; DDP 80 mg/m², d1; W1, 5	157	-	-	-	-	5 y 71%	?	-	-
ACT II	肛管或肛周癌，任何T任何NM0	50.4 Gy/28 F	RT+5FU/MMC	5FU 1000 mg/m²/d, civ, d1~4, 29~32; MMC iv 12 mg/m², d1	246	23%	-	?	-	DDP:77% MMC:79%辅助：76%未辅助：79%	NS	?	NS
			RT+5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; DDP 60 mg/m², d1, 29	246	26%		?				?
			RT+5FU/MMC-5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; MMC iv 12 mg/m², d1辅助化疗5FU 1000 mg/m²/d, civ, d71~74, 92~95; DDP 60 mg/m², d71, 92	226	23%		?				?
			RT+5FU/DDP-5FU/DDP	5FU 1000 mg/m²/d, civ, d1~4, 29~32; DDP 60 mg/m², d1, 29辅助化疗同上	222	22%		?				?

[1]	Martin, F.T., D. Kavanagh, R. Waldron.Squamous cell carcinoma of the anal canal. Surgeon, 2009, 7(4): 232-237.
[2]	Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61(4): 212-236.
[3]	Metildi C, McLemore EC, Tran T, et al. Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry. Am Surg, 2013. 79(10): 1068-1074.
[4]	Melbye M, Rabkin C, Frisch M,et al. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol, 1994, 139(8): 772-780.
[5]	Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer, 2004, 101(2): 281-288.
[6]	Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 1974. 17(3): 354-356.
[7]	Myerson RJ, Karnell LH, Menck HR.The National Cancer Data Base report on carcinoma of the anus. Cancer, 1997, 80(4): 805-815.
[8]	Frost DB, Richards PC, Montague ED,et al. Epidermoid cancer of the anorectum. Cancer, 1984, 53(6): 1285-1293.
[9]	Bilimoria KY, Bentrem DJ, Rock CE,et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum, 2009, 52(4): 624-631.
[10]	Ortholan C, Resbeut M, Hannoun-Levi JM, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys, 2012, 82(5): 1988-1995.
[11]	Cummings BJ, Keane TJ, O’Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys, 1991, 21(5): 1115-1125.
[12]	UKCCCR Anal Cancer Trial Working Party.Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet, 1996, 348(9034): 1049-1054.
[13]	Northover J, Glynne-Jones R, Sebag-Montefiore D,et al.Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer, 2010, 102(7): 1123-1128.
[14]	Bartelink H, Roelofsen F, Eschwege F,et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol, 1997, 15(5): 2040-2049.
[15]	Flam M, John M, Pajak TF,et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol, 1996, 14(9): 2527-2539.
[16]	Matzinger O, Roelofsen F, Mineur L, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer, 2009, 45(16): 2782-2791.
[17]	Glynne-Jones R, Meadows H, Wan S,et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys, 2008, 72(1): 119-126.
[18]	Friberg B, Svensson C, Goldman S, et al. The Swedish National Care Programme for Anal Carcinoma-implementation and overall results. Acta Oncol, 1998, 37(1): 25-32.
[19]	Goldman S, Glimelius B, Glas U,et al.Management of anal epidermoid carcinoma-an evaluation of treatment results in two population-based series. Int J Colorectal Dis, 1989, 4(4): 234-243.
[20]	Nilsson PJ, Svensson C, Goldman S,et al.Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys, 2005, 61(1): 92-102.
[21]	Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA, 2008, 299(16): 1914-1921.
[22]	Tournier-Rangeard L, Mercier M, Peiffert D,et al. Radiochemotherapy of locally advanced anal canal carcinoma: Prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). Radiotherapy and Oncology, 2008, 7(3): 391-397.
[23]	NIH Clinical Trials Registry. Available at: URL
[24]	Levy A, Azria D, Pignon JP,et al. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol, 2015, 14(3): 415-416.
[25]	Tanum G, Hannisdal E, Stenwig B. Prognostic factors in anal carcinoma. Pathology, 2002. 34(6): 573-578.
[26]	Ajani JA, Wang X, Izzo JG, et al. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. Digestive Diseases and Sciences, 2010, 5(4): 1098-1105.
[27]	Bruland O, Fluge O, Immervoll H, et al. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer, 2008, 8(7): 1264-1273.

[1]	史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(08): 778-784.
[2]	易柏成, 李旭光, 王容容, 王新璇. 数字化3D打印导板应用于上前牙钙化根管治疗2例[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 385-390.
[3]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6]	孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[7]	刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8]	刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9]	石海波, 赵旭东, 王聪, 曲巍. 气肿性肾盂肾炎、气肿性膀胱炎并脓毒性休克一例报道并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 644-647.
[10]	林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊（第15期）——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[11]	陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[12]	刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[13]	王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14]	丁洪基, 赵长江, 孙鹏飞, 王灿, 王贵珍, 李龙龙. 细胞焦亡与疾病的关系研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 682-686.
[15]	崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

The progress in the treatment of anal canal cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

The progress in the treatment of anal canal cancer